EXOZYMES INC.

EXOZYMES INC. has filed an S-1 registration statement with the SEC for a proposed public offering of its common stock and purchase warrants. The company is offering a combination of shares and warrants, with each warrant entitling the holder to purchase one share of common stock. EXOZYMES INC. has elected to be treated as an emerging growth company and a smaller reporting company. The common stock is listed on The Nasdaq Capital Market under the symbol 'EXOZ', and Newbridge Securities Corporation is acting as the sole book-running manager for this offering.

EXOZYMES INC. reported a net loss of $(2.88) million for the three months ended June 30, 2026, and $(5.25) million for the six months ended June 30, 2026, compared to $(2.36) million and $(4.22) million for the respective periods in 2025. The company disclosed substantial doubt about its ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status. To address this, EXOZYMES completed an underwritten public offering and a concurrent registered direct offering in June 2026, generating net proceeds of $5.86 million from the issuance of common stock and warrants.

EXOZYMES INC. reported a net loss of $(2.88) million for the second quarter of 2026 and $(5.25) million for the six months ended June 30, 2026. The net loss per common share was $(0.33) for the quarter and $(0.61) for the six-month period. Despite these losses, the company successfully raised net proceeds of $5.86 million from a public offering and a concurrent registered direct offering of common stock and warrants in June 2026. Management expressed substantial doubt about the company's ability to continue as a going concern due to anticipated funding shortfalls and its pre-revenue status, highlighting the need for additional financial support.

eXoZymes Inc. announced it has been awarded a $2,028,518 Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This significant non-dilutive funding will be used to advance cannabinoid analogs for drug discovery, expanding the company's portfolio of proprietary molecules and potential future pharmaceutical assets. The award brings eXoZymes' total non-dilutive funding to nearly $20 million and marks the second biosolution in its pipeline advancing towards partnership and commercialization, with work expected to begin on July 1, 2026.

eXoZymes Inc. announced the closing of its underwritten public offering, including the partial exercise of an over-allotment option. The offering generated gross proceeds of approximately $5.95 million before deducting underwriting discounts and expenses. The company sold a total of 330,575 units, with each unit comprising two shares of common stock and one warrant. Net proceeds are intended to support development and commercialization activities for N-trans-caffeoyltyramine ("NCT"), advance additional product opportunities, fund research and development, and for working capital and other general corporate purposes.

eXoZymes Inc. announced the pricing of a public offering of units, each comprising two shares of common stock and one warrant, at $18.00 per unit. The offering is expected to generate approximately $5.33 million in gross proceeds. The company plans to use the net proceeds for business development, research and development, and general corporate purposes. The warrants have specific terms regarding exercise price, reset provisions, and redemption.

EXOZYMES INC. reported a net loss of $2.37 million for the three months ended March 31, 2026, a significant increase from $1.86 million in the prior year. The company's cash and cash equivalents decreased by over 50% to $1.44 million, and it continued to use substantial cash in operations, leading to a going concern warning. Research and development costs nearly doubled, while general and administrative costs saw a slight decrease. The company's total assets and equity also saw significant declines.

EXOZYMES INC. has filed an Investor Presentation dated April 10, 2026, with the SEC. This presentation is being distributed to potential underwriters and other participants for a proposed securities offering by the company. The filing indicates the company is actively moving forward with plans to raise capital.